What we are studying
The purpose of this research study is to see if Apremilast works by blocking an enzyme in the body called phosphodiesterase 4 (PDE4) that is usually elevated in medical conditions involving inflammation, such as inflammation of the skin in psoriasis. Apremilast is in the form of tablets and is taken by mouth. Apremilast has been approved in approximately 40 countries worldwide, including Canada and the U.S. for the treatment of moderate to severe plaque psoriasis. The use of apremilast in this study is considered investigational as there is no current data in the Clinical Studies section of the US label regarding effectiveness and safety of apremilast treatment for scalp psoriasis lesions.The study will test apremilast and compare its effects with placebo in the treatment of moderate to severe scalp and body psoriasis. A placebo does not have any active medication but looks exactly like the study drug (apremilast) tablet. This study will test how well your body tolerates apremilast, and how successfully apremilast treats your psoriasis.
You will be paid $550 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $50 for each complete study visit.